DGAP-Adhoc: Biotest AG: Biotest AG plans a capital increase and rights issue

Biotest AG / Key word(s): Capital Increase

08.05.2013 11:15

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Biotest AG plans a capital increase and rights issue

Dreieich, 8 May 2013 - Today, Management Board and Supervisory Board of
Biotest AG have resolved on a planned capital increase from authorised
capital against cash contributions.

Biotest AG plans to increase its share capital from EUR 30,025,152.00 by up
to EUR 3,742,487.04 to up to EUR 33,767,639.04 by issuing up to 1,461,909
new, no-par value preferred bearer shares (shares without nominal value) of
Biotest AG. The new Shares shall be offered to the shareholders by way of
indirect subscription right in accordance with a subscription ratio of
8 : 1.

It is expected that the Management Board will decide on the implementation
of the projected capital increase with the approval of the Supervisory
Board within the second or third quarter of the current year 2013.

The proposed capital increase shall serve the financing of Biotest AG's
growth strategy which also entails to increase its production capacities at
its central manufacturing site at Dreieich. Besides this the offer is aimed
to increase the number of shares in free float and the liquidity in the
shares of Biotest AG.

Biotest Aktiengesellschaft
The Management Board
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
Germany
www.biotest.de

ISIN: DE0005227235; DE0005227201
WKN: 522723; 522720

This publication does neither constitute an offer to sell nor a
solicitation of an offer to buy or subscribe for any securities. The
information contained in this publication may not be released in or
distributed within the United States of America, Canada, Japan or
Australia.

Disclaimer

This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of rheumatoid arthritis and cancer of plasma cells,
which are produced by recombinant technologies. Biotest has about 1.800
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart

---------------------------------------------------------------------------

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------